KalVista Pharmaceuticals (KALV) Shareholder's Equity Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -76.39% |
| Apr 30, 2025 | -53.82% |
| Oct 31, 2024 | 17.08% |
| Jul 31, 2024 | 24.02% |
| Apr 30, 2024 | 28.29% |
| Jan 31, 2024 | -51.97% |
| Oct 31, 2023 | -20.42% |
| Jul 31, 2023 | -15.33% |
| Apr 30, 2023 | -13.00% |
| Jan 31, 2023 | -11.30% |
| Oct 31, 2022 | -36.78% |
| Jul 31, 2022 | -32.67% |
| Apr 30, 2022 | -28.03% |
| Jan 31, 2022 | 255.05% |
| Oct 31, 2021 | 250.06% |
| Jul 31, 2021 | 228.38% |
| Apr 30, 2021 | 207.09% |
| Jan 31, 2021 | -34.74% |
| Oct 31, 2020 | -33.55% |
| Jul 31, 2020 | -26.93% |
| Apr 30, 2020 | -13.42% |
| Jan 31, 2020 | -13.73% |
| Oct 31, 2019 | -8.57% |
| Jul 31, 2019 | 288.06% |
| Apr 30, 2019 | 254.96% |
| Jan 31, 2019 | 264.17% |
| Oct 31, 2018 | 244.09% |
| Jul 31, 2018 | -1.81% |
| Apr 30, 2018 | -13.00% |
| Jan 31, 2018 | -18.03% |
| Mar 31, 2016 | 187.96% |
| Dec 31, 2015 | 211.61% |